{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:42:27Z","timestamp":1784544147818,"version":"3.55.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004697","name":"Hamadan University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.msard.2022.103857","type":"journal-article","created":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T11:35:31Z","timestamp":1651923331000},"page":"103857","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study"],"prefix":"10.1016","volume":"63","author":[{"given":"Rashed","family":"Bawand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9632-8558","authenticated-orcid":false,"given":"Masoud","family":"Ghiasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Negin","family":"Fathoallahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Moradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103857_bib0044","doi-asserted-by":"crossref","unstructured":"Ahmadi S.A., Kazemi A., Sabahi M., et\u00a0al. Probable antioxidant therapy of Saffron Crocin in patients with multiple sclerosis: a randomized controlled trial. 2020;40(4):516\u2013521.","DOI":"10.51248\/.v40i4.332"},{"key":"10.1016\/j.msard.2022.103857_bib0013","doi-asserted-by":"crossref","unstructured":"Ahn S.-.G., Lim H.-.S., Joe D-Y, et\u00a0al. Relationship of epicardial adipose tissue by echocardiography to coronary artery disease. 2008;94(3):e7\u2013e7.","DOI":"10.1136\/hrt.2007.118471"},{"key":"10.1016\/j.msard.2022.103857_bib0031","unstructured":"AISM Italian Multiple Sclerosis Society. https:\/\/in-tour.eu\/consortium\/aism-italian-multiple-sclerosis-society, 2020."},{"key":"10.1016\/j.msard.2022.103857_bib0022","unstructured":"Brunton LLKBrCH-DR. Goodman & Gilman's: the Pharmacological Basis of Therapeutics. 2018."},{"key":"10.1016\/j.msard.2022.103857_bib0006","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CEOR.S130334","article-title":"Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis","volume":"9","author":"Burks","year":"2017","journal-title":"ClinicoEcon. Outcomes Res.: CEOR"},{"key":"10.1016\/j.msard.2022.103857_bib0039","doi-asserted-by":"crossref","unstructured":"Confavreux C., Hutchinson M., Hours M.M., Cortinovis-Tourniaire P., Moreau T., Medicine PiMSGJNEJo. Rate of pregnancy-related relapse in multiple sclerosis. 1998;339(5):285\u2013291.","DOI":"10.1056\/NEJM199807303390501"},{"key":"10.1016\/j.msard.2022.103857_bib0041","doi-asserted-by":"crossref","unstructured":"Corallo F., Bonanno L., Di Cara M., et\u00a0al. Therapeutic adherence and coping strategies in patients with multiple sclerosis: an observational study. 2019;98(29).","DOI":"10.1097\/MD.0000000000016532"},{"key":"10.1016\/j.msard.2022.103857_bib0035","doi-asserted-by":"crossref","unstructured":"Decoo D., Vokaer MJPp, adherence. Treatment adherence in multiple sclerosis: a survey of Belgian neurologists. 2015;9:1669.","DOI":"10.2147\/PPA.S91973"},{"key":"10.1016\/j.msard.2022.103857_bib0023","doi-asserted-by":"crossref","unstructured":"Devonshire V., Lapierre Y., Macdonell R., et\u00a0al. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. 2011;18(1):69\u201377.","DOI":"10.1111\/j.1468-1331.2010.03110.x"},{"key":"10.1016\/j.msard.2022.103857_bib0033","unstructured":"European Multiple Sclerosis Platform (EMSP). https:\/\/emsp.org\/, 2020."},{"key":"10.1016\/j.msard.2022.103857_bib0028","doi-asserted-by":"crossref","unstructured":"Feicke J., Sp\u00f6rhase U., K\u00f6hler J., Busch C., Wirtz M. A multicenter, prospective, quasi-experimental evaluation study of a patient education program to foster multiple sclerosis self-management competencies. Patient Educ. Couns.. 2014, \/12\/01\/2014;97(3):361\u2013369. doi:https:\/\/doi.org\/10.1016\/j.pec.2014.09.005.","DOI":"10.1016\/j.pec.2014.09.005"},{"issue":"10","key":"10.1016\/j.msard.2022.103857_bib0007","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1080\/03007995.2018.1451311","article-title":"First-line disease-modifying drugs in relapsing\u2013remitting multiple sclerosis: an Italian real-life multicenter study on persistence","volume":"34","author":"Ferraro","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2022.103857_bib0017","doi-asserted-by":"crossref","unstructured":"P. FJPp, adherence. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. 2010;4:1.","DOI":"10.2147\/PPA.S8230"},{"key":"10.1016\/j.msard.2022.103857_bib0008","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.msard.2017.10.001","article-title":"The impact of treatment adherence on clinical and economic outcomes in multiple sclerosis: real world evidence from Alberta, Canada","volume":"18","author":"Gerber","year":"2017","journal-title":"Multiple sclerosis and related disorders"},{"key":"10.1016\/j.msard.2022.103857_bib0043","doi-asserted-by":"crossref","unstructured":"Ghiasian M., Khamisabadi F., Kheiripour N., et\u00a0al. Effects of crocin in reducing DNA damage, inflammation, and oxidative stress in multiple sclerosis patients: a double-blind, randomized, and placebo-controlled trial. 2019;33(12):e22410.","DOI":"10.1002\/jbt.22410"},{"key":"10.1016\/j.msard.2022.103857_bib0040","doi-asserted-by":"crossref","unstructured":"Ghiasian M., Nouri M., Moghadasi A.N., Ghaffari MJCN, Neurosurgery. Effect of pregnancy and exclusive breastfeeding on multiple sclerosis relapse rate and degree of disability within two years after delivery. 2020;194:105829.","DOI":"10.1016\/j.clineuro.2020.105829"},{"key":"10.1016\/j.msard.2022.103857_bib0045","doi-asserted-by":"crossref","unstructured":"Ghiasian M., Nafisi H., Ranjbar A., Mohammadi Y., Ataei SJJob, toxicology m. Antioxidative effects of silymarin on the reduction of liver complications of fingolimod in patients with relapsing\u2013remitting multiple sclerosis: a clinical trial study. 2021;35(8):e22800.","DOI":"10.1002\/jbt.22800"},{"key":"10.1016\/j.msard.2022.103857_bib0014","doi-asserted-by":"crossref","unstructured":"Hansen K., Sch\u00fcssel K., Kieble M., et\u00a0al. Adherence to disease modifying drugs among patients with multiple sclerosis in Germany: a retrospective cohort study. 2015;10(7):e0133279.","DOI":"10.1371\/journal.pone.0133279"},{"issue":"12","key":"10.1016\/j.msard.2022.103857_bib0025","first-page":"737","article-title":"Measuring adherence and outcomes in the treatment of patients with multiple sclerosis","volume":"117","author":"Hao","year":"2017","journal-title":"J. Am. Osteopath. Assoc."},{"issue":"13","key":"10.1016\/j.msard.2022.103857_bib0003","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1177\/1352458514531348","article-title":"Adherence in multiple sclerosis (ADAMS): classification, relevance, and research needs. A meeting report","volume":"20","author":"Heesen","year":"2014","journal-title":"Mult. Scler.s J."},{"key":"10.1016\/j.msard.2022.103857_bib0034","unstructured":"Iran MS society. http:\/\/www.iranms.ir\/, 2020."},{"key":"10.1016\/j.msard.2022.103857_bib0037","doi-asserted-by":"crossref","unstructured":"Jernas \u0141., Wencel J., Wiak A., Bieniek M., B.-.P. HJPo. Risk factors for poor adherence to Betaferon\u00ae treatment in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome. 2016;11(10):e0157950.","DOI":"10.1371\/journal.pone.0157950"},{"issue":"1","key":"10.1016\/j.msard.2022.103857_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1477-7525-8-133","article-title":"Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study","volume":"8","author":"Jongen","year":"2010","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.msard.2022.103857_bib0010","doi-asserted-by":"crossref","unstructured":"Jongen P.J., Sindic C., Carton H., Zwanikken C., Lemmens W., B. GJJon. Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a. 2010;257(4):584\u2013589.","DOI":"10.1007\/s00415-009-5378-x"},{"key":"10.1016\/j.msard.2022.103857_bib0027","doi-asserted-by":"crossref","unstructured":"Kohlmann T., Wang C., Lipinski J., et\u00a0al. The impact of a patient support program for multiple sclerosis on patient satisfaction and subjective health status. 2013;45(3):E3\u2013E14. doi:10.1097\/JNN.0b013e31828a4161.","DOI":"10.1097\/JNN.0b013e31828a4161"},{"key":"10.1016\/j.msard.2022.103857_bib0042","doi-asserted-by":"crossref","unstructured":"Lahdenper\u00e4 S., Soilu-H\u00e4nninen M., Kuusisto H.M., Atula S., Junnila J., Berglund AJANS. Medication adherence\/persistence among patients with active multiple sclerosis in Finland. 2020;142(6):605\u2013612.","DOI":"10.1111\/ane.13301"},{"key":"10.1016\/j.msard.2022.103857_bib0019","unstructured":"Louis EDMSARLP. Merritt's neurology. 2015."},{"issue":"8","key":"10.1016\/j.msard.2022.103857_bib0001","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2022.103857_bib0002","first-page":"S24","article-title":"Pill MW. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis","volume":"19","author":"Menzin","year":"2013","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.msard.2022.103857_bib0015","doi-asserted-by":"crossref","unstructured":"Menzin J., Caon C., Nichols C., White L.A., Friedman M., Pill MWJJomcp. Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis. 2013;19(1 Supp A):S24\u2013S40.","DOI":"10.18553\/jmcp.2013.19.s1.S24"},{"key":"10.1016\/j.msard.2022.103857_bib0021","doi-asserted-by":"crossref","unstructured":"Meyer-Moock S., Feng Y.-.S., Maeurer M., Dippel F.-.W., K. TJBn. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. 2014;14(1):1\u201310.","DOI":"10.1186\/1471-2377-14-58"},{"key":"10.1016\/j.msard.2022.103857_bib0030","unstructured":"MS Society. https:\/\/www.mssociety.org.uk\/, 2020."},{"key":"10.1016\/j.msard.2022.103857_bib0026","doi-asserted-by":"crossref","unstructured":"Nicholas J.A., Edwards N.C., Edwards R.A., Dellarole A., Grosso M., P. ALJBn. Real-world adherence to, and persistence with, once-and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis. 2020;20(1):1\u201315.","DOI":"10.1186\/s12883-020-01830-0"},{"key":"10.1016\/j.msard.2022.103857_bib0004","unstructured":"Organization WH. Diet, nutrition, and the prevention of chronic diseases: report of a joint WHO\/FAO expert consultation. vol 916. World Health Organization; 2003."},{"key":"10.1016\/j.msard.2022.103857_bib0016","unstructured":"Pirdehghan A., P. NJJorihs. Predictors of adherence to type 2 diabetes medication. 2016;16(2):72."},{"key":"10.1016\/j.msard.2022.103857_bib0018","doi-asserted-by":"crossref","unstructured":"Polman C.H., Reingold S.C., Banwell B., et\u00a0al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. 2011;69(2):292\u2013302.","DOI":"10.1002\/ana.22366"},{"issue":"3","key":"10.1016\/j.msard.2022.103857_bib0024","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1191\/1352458505ms1173oa","article-title":"Factors related with treatment adherence to interferon b and glatiramer acetate therapy in multiple sclerosis","volume":"11","author":"R\u00edo","year":"2005","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2022.103857_bib0020","unstructured":"Ropper AHSMAKJPS. Adams and Victor's principles of neurology. 2015."},{"key":"10.1016\/j.msard.2022.103857_bib0005","series-title":"Adherence to Long-Term Therapies: Evidence for Action","author":"Sabat\u00e9","year":"2003"},{"key":"10.1016\/j.msard.2022.103857_bib0038","doi-asserted-by":"crossref","unstructured":"Sauri-Su\u00e1rez S., Qui\u00f1ones-Aguilar S., Contreras-Mar\u00edn A., et\u00a0al. Adherence to self-administering interferon-\u03b21a using RebiSmart\u00ae device in Mexican patients with relapsing multiple sclerosis. 2020;15(4):e0230959.","DOI":"10.1371\/journal.pone.0230959"},{"key":"10.1016\/j.msard.2022.103857_bib0032","unstructured":"The MS Registry. https:\/\/www.msregister.de\/en\/ms-register\/das-ms-register\/, 2020."},{"key":"10.1016\/j.msard.2022.103857_bib0029","unstructured":"The National MS Society https:\/\/www.nationalmssociety.org\/, 2020."},{"key":"10.1016\/j.msard.2022.103857_bib0011","doi-asserted-by":"crossref","unstructured":"Trojano M., Paolicelli D., Lepore V., et\u00a0al. Italian multiple sclerosis database network. 2006;27(5):s358-s361.","DOI":"10.1007\/s10072-006-0694-8"},{"key":"10.1016\/j.msard.2022.103857_bib0012","doi-asserted-by":"crossref","unstructured":"Vermeire E., Hearnshaw H., Van Royen P., Denekens JJJocp, therapeutics. Patient adherence to treatment: three decades of research. Compr. Rev. 2001;26(5):331\u2013342.","DOI":"10.1046\/j.1365-2710.2001.00363.x"},{"key":"10.1016\/j.msard.2022.103857_bib0036","doi-asserted-by":"crossref","unstructured":"Yano H., Gonzalez C., Healy B.C., et\u00a0al. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: effect on clinical and MRI outcomes. 2019;35:119\u2013127.","DOI":"10.1016\/j.msard.2019.07.021"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:59:52Z","timestamp":1761901192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822003698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":45,"alternative-id":["S2211034822003698"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103857","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of disease-modifying treatments discontinuation in patients with relapsing-remitting multiple sclerosis: A 5 year prospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103857","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103857"}}